It was reported that higher plasma IL18 levels were associated with shorter recurrence-free survival (RFS) and overall survival (OS) in patients with triple-negative breast cancer [37], and IL18 overexpression in tumors was associated with shorter OS in patients with pancreatic cancer [38]. Here, IL18 is linked to triple-negative breast carcinoma.